The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: A randomized, double-blind, placebo-controlled, noninferiority trial

Anesthesia and Analgesia

Volumn 109, Issue 1, 2009, Pages 15-24

  Greilich, Philip E ^a,e   Jessen, Michael E ^a   Satyanarayana, Neeraj ^a   Whitten, Charles W ^a   Nuttall, Gregory A ^b   Beckham, Joseph M ^a   Wall, Michael H ^c   Butterworth, John F ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Mayo Clinic   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; APROTININ; D DIMER; HEPARIN; PLACEBO; PROTAMINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COST; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA TRANSFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THORAX DRAINAGE; THROMBOCYTE TRANSFUSION; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

6-AMINOCAPROIC ACID; AGED; APROTININ; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 67650687046     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181a40b5d     Document Type: Article

References (42)

1. Ferraris VA, Ferraris SP, Saha SP, Hessel EA II, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the society of thoracic surgeons and the society of cardiovascular anesthesiologists clinical practice guideline. Ann Thorac Surg 2007;83: S27-S86
2. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-83
3. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994;5:537-42
4. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61
5. Slaughter TF, Faghih F, Greenberg CS, Leslie JB, Sladen RN. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997;85: 1221-6
6. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83
7. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussieres JS, Cote D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31
8. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65
9. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, Hoeft A, Fontes ML, Hillel Z, Ott E, Titov T, Dietzel C, Levin J. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9
10. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008;358: 784-93
11. Eberle B, Mayer E, Hafner G, Heinermann J, Dahm M, Prellwitz W, Dick W, Oelert H. High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations. Ann Thorac Surg 1998;65:667-73
12. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg 1999;68:2252-6; discussion 2256-7
13. Menichetti A, Tritapepe L, Ruvolo G, Speziale G, Cogliati A, Di Giovanni C, Pacilli M, Criniti A. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg (Torino) 1996;37:401-7
14. Penta de Peppo A, Pierri MD, Scafuri A, De Paulis R, Colantuono G, Caprara E, Tomai F, Chiariello L. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 1995;22:231- 6
15. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman B, Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998;116:716-30
16. Dietrich W, Schopf K, Spannagl M, Jochum M, Braun SL, Meisner H. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann Thorac Surg 1998;65:70-7; discussion 77-8
17. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26
18. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62-9
19. Food and Drug Administration, HHS. International Conference on Harmonisation; choice of control group and related issues in clincal trials; availability. Notice. Fed Regist 2001;66:24390-1
20. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthe-siology 1995;82:383-92
21. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-22; discussion 822-3
22. Greilich PE, Brouse CF, Rinder CS, Smith BR, Sandoval BA, Rinder HM, Eberhart RC, Jessen ME. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004; 100:225-33
23. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003;126:1498-503
24. Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation 2001;104:I265-I269
25. Dentz ME, Slaughter TF, Mark JB. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology 1995;82:583-6
26. Butterworth J, James RL, Lin Y, Prielipp RC, Hudspeth AS. Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999; 90:1624-35
27. Curtin N, Highe G, Harris M, Braunstein A, Demattia F, Coss L. Extensive evaluation of the instrumentation laboratory IL test D-Dimer immunoturbidimetric assay on the ACL 9000 determines the D-Dimer cutoff value for reliable exclusion of venous thromboembolism. Lab Hematol 2004;10:88-94
28. Nuttall GA, Fass DN, Oyen LJ, Oliver WC Jr, Ereth MH. A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg 2002;94:283-9, table of contents
29. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1997;113:611-13
30. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13
31. Lasocki S, Provenchere S, Benessiano J, Vicaut E, Lecharny JB, Desmonts JM, Dehoux M, Philip I. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. Anesthesiology 2002;97:405-11
32. Karski JM, Teasdale SJ, Norman P, Carroll J, VanKessel K, Wong P, Glynn MF. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid. Double-blind, randomized clinical trial. J Thorac Cardiovasc Surg 1995;110:835-42
33. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley and Sons, 1973:75-82
34. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981;673:75-85
35. Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996; 112:1098-107
36. Ferraris VA, Ferraris SP, Moliterno DJ, Camp P, Walenga JM, Messmore HL, Jeske WP, Edwards FH, Royston D, Shahian DM, Peterson E, Bridges CR, Despotis G. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 2005;79:1454-61
37. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005;5:19
38. Bennett-Guerrero E, Sorohan JG, Gurevich ML, Kazanjian PE, Levy RR, Barbera AV, White WD, Slaughter TF, Sladen RN, Smith PK, Newman MF. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 1997;87:1373-80
39. Bennett-Guerrero E, Sorohan JG, Canada AT, Ayuso L, Newman MF, Reves JG, Mythen MG. epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. Anesth Analg 1997;85: 248-51
40. Bridges CR. Valid comparisons of antifibrinolytic agents used in cardiac surgery. Circulation 2007;115:2790-2
41. Myles PS, Smith J, Knight J, Cooper DJ, Silbert B, McNeil J, Esmore DS, Buxton B, Krum H, Forbes A, Tonkin A. Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: rationale and design. Am Heart J 2008;155:224-30
42. Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005;103:229-40